J. E. Bennett

Research output: Contribution to journalReview articlepeer-review


Flucytosine is a systemic antifungal drug that is readily absorbed from the gastrointestinal tract. The most clearly documented therapeutic effect has been in cryptococcosis, candidiasis, and chromomycosis. An important limitation of the use of flucytosine in all 3 diseases has been drug resistance arising during therapy. The addition of low-dose, intravenous amphotericin B to flucytosine therapy of cryptococcosis has appeared to decrease the frequency of secondary flucytosine resistance. In addition, the 2 drugs have an additive or slightly synergistic effect against flucytosine susceptible isolates of Cryptococcus and Candida. The combination is probably the treatment of choice in cryptococcal meningitis and offers promise in the therapy of systemic candidiasis and nonmeningeal cryptococcosis.

Original languageEnglish (US)
Pages (from-to)319-322
Number of pages4
JournalAnnals of internal medicine
Issue number3
StatePublished - Jan 1 1977

ASJC Scopus subject areas

  • Internal Medicine


Dive into the research topics of 'Flucytosine'. Together they form a unique fingerprint.

Cite this